ChemBriefNovartis strikes about $7.8 billion mRNA deal with China's Abogen
Novartis has entered into a $7.8 billion licensing and option agreement with Chinese biotech firm Abogen to advance RNA-based therapies.
reuters · 2026-10-02 00:31 UTC
Novartis has entered into a $7.8 billion licensing and option agreement with Chinese biotech firm Abogen to advance RNA-based therapies.
European shares declined as rising crude oil prices fueled inflation fears, while Novartis stock tumbled following two failed late-stage drug trials. Meanwhile, Sandoz gained ground on ambitious sales
European markets declined amid inflation fears from rising oil prices linked to U.S.-Iran tensions. Novartis shares fell after its experimental drug pelacarsen missed a key late-stage trial goal.
Novartis shares fell 3.3% after its cholesterol drug pelacarsen failed a late-stage study targeting high Lp(a) levels. This setback increases pressure on the company's gene therapy pipeline and impact
Novartis plans to relocate laboratory and biologics production activities from its Kleinbasel site to its main campus, potentially cutting around 130 jobs by 2028. The move aligns with lease expiratio
Novartis reported a second-quarter profit beat and maintained its 2026 outlook despite facing patent cliffs on key drug Entresto. The company highlighted upcoming trial results for three experimental
Swiss drugmaker Novartis plans to shut down its Wehr production site by late 2028, eliminating around 220 jobs. The facility produced tablets and capsules but was deemed uncompetitive.
Pharmaceutical services firms unveiled major manufacturing expansions at DCAT Week, including Cambrex's $130 million API project in Iowa and BSP Pharmaceuticals' $800 million investment in antibody-dr